Which of the following product risks would be most effectively addressed just by static testing? 3 credits
Since the system is in the medical domain and therefore in the safety critical area, testing needs to be rigorous and evidence is required that the system has been adequately tested. Identify THREE measures that would typically be part of the test approach in this domain and which are not always applicable in other domains! 1 credit
Which THREE activities would be valid steps during the development of the test strategy?2 credits (2 out of 3 correct 1 credit)
SoftTech provides a core banking product to retail banks to enable their customers to process payments via the Internet and telephone banking and. as SoftTech's Test Manager, you are responsible for system testing and system integration testing of all SoftTech's products.
Your current project is to integrate SoftTech's core banking product with an existing bank's systems, which are maintained by experienced developers but poorly documented.
A specification for the 10 interfaces to the bank's existing systems has been produced by SoftTech's development team. There is an estimating matrix for system integration testing that allows 2 man days per interface for preparation, plus 2 man days per interface for test execution. The exit criteria for the completion of system integration testing has been agreed as:
1. No open Severity 1 defects
2 No more than 10 open severity 2 and/or 3 defects
3. All interfaces tested
4. Cost estimate must not be exceeded
System integration test execution is scheduled to last 5 weeks, with week 5 reserved for regression and bug fixing only. At the end of week 3 the following test report has been produced (figures on a week by week basis, not cumulative):
b. Open severity 2 and 3 defects
c. Interface testing progress
d. Development resource for debugging
e. Available budget
SELECT ONE OPTION
You have recently implemented a new defect management process which now includes a defect triage committee whose job is to review all new defects. The process is shown in the following diagram:
b. The total number of defects rejected as not a problem following investigation by the product author c. The number of defects returned to the defect author, expressed as a percentage of all defects raised d. The total number of defects that failed re-test more than once e. The total number of defects closed by the defect triage committee SELECT ONE OPTION
